In addition to high antibody levels, factors including exposure to the human papillomavirus (HPV) and antibody avidity may be important and necessary to protect against infection.
Despite reassuring safety data from clinical trials, the adoption of the inactivated HPV vaccine in the United States remains low.
Survey results reveal HPV vaccine delivery practices and experiences among pediatricians and family physicians.
Studies based on searching Vaccine Adverse Event Reporting System, 6 Vaccine Safety Datalink sites.
Human papillomavirus DNA is detected in the oral cavities of about 6.2% of sexually active female adolescents,
In 2018, adolescent vaccination coverage in the United States continued to improve for meningococcal and HPV vaccines and remains high for tetanus and reduced diphtheria toxoids and acellular pertussis vaccine.
For adults aged 27 to 45 years, vaccination may be beneficial for some who are inadequately vaccinated.
Educational videos produced the highest rate of acceptability and knowledge.
Prevalence of HPV 16 and 18 decreased; anogenital wart diagnoses down in girls, women, boys, men.
Most lifetime QALYs seen with cytologic testing every 3 years, repeated for ASC-US.
Antibody titers to the HPV4 vaccine were lower for all HPV serotypes in individuals who were infected with HIV perinatally than those who were exposed to HIV perinatally.
Compared with liquid-based cytology, routine primary hrHPV screening better detected cervical intraepithelial neoplasia grade 3 or worse and cervical cancer.
Parents of racial or ethnic minority adolescents were more likely to inaccurately report HPV vaccination initiation.
Only 15.7 and 34.8% of teens completed HPV vaccination before turning 13 and 15.
The prevalence of anogenital warts has decreased, with significant declines observed in specific populations.
Women who used a self-screening assay for high-risk human papillomavirus had similar test results to those who were screened by a clinician.
HIV-infected Hispanics have an increased risk for human papillomavirus-related cancers than Hispanics in the general population.
Women with high-risk human papillomavirus-positive cervical tumors have a substantially better prognosis than women with hrHPV-negative tumors.
The approval of the expanded age range was based on data from a clinical trial which evaluated the efficacy of Gardasil (quadrivalent human papillomavirus recombinant vaccine) in 3253 women 27-45 years of age with a median duration of follow-up of 3.5 years post-dose 3.
14 million need to receive two doses of vaccine to reach goal of 80% vaccination by 2026.